- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00605176
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses
The purpose of this study is to determine whether imiquimod creams are effective in treating Actinic Keratoses when applied to the face or balding scalp.
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The active ingredient contained in the study cream for this study is the same as that of the approved product Aldara, which has been shown to be safe and effective for the treatment of AKs.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized, double-blind, multicenter, placebo-controlled study that compared the efficacy and safety of 2.5% imiquimod cream and 3.75% imiquimod cream with that of placebo in the treatment of typical visible or palpable AKs of the face or balding scalp. Subjects were scheduled for a total of 9 visits (1 prestudy screening visit and 8 on-study visits). Subjects determined to be eligible during the screening phase were randomized in a 1:1:1 ratio to 2.5% imiquimod cream, 3.75% imiquimod cream, or placebo cream. The creams were applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment. The investigator selected the treatment area for the study (either the entire face or the entire balding scalp, but not both). Subjects applied a thin layer of cream to the treatment area (up to 2 packets, or 500 mg of product, per application), avoiding the periocular areas, lips, and nares. Study medication was applied prior to normal sleeping hours and removed approximately 8 hours later with mild soap and water. Ears were excluded from both assessment and treatment. Rest periods from daily treatment were instituted by the investigator as needed to manage local skin reactions (LSRs) or application site reactions, with resumption of treatment upon adequate resolution as determined by the investigator.
The duration of each subject's study participation was approximately 18 weeks, including a 4-week maximum screening period and a 14-week study period.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Fremont, California, United States, 94538
-
Los Angeles, California, United States, 90045
-
Riverside, California, United States, 92506
-
San Diego, California, United States, 92117
-
Vallejo, California, United States, 94589
-
-
Florida
-
Miami, Florida, United States, 33144
-
-
Georgia
-
Newman, Georgia, United States, 30263
-
-
Idaho
-
Boise, Idaho, United States, 83704
-
-
Illinois
-
Springfield, Illinois, United States, 62703
-
-
Iowa
-
Dubuque, Iowa, United States, 52002
-
-
Kansas
-
Olathe, Kansas, United States, 66061
-
Wichita, Kansas, United States, 67206
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
-
-
Nevada
-
Henderson, Nevada, United States, 89052
-
-
New York
-
Rochester, New York, United States, 14623
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
-
Winston Salem, North Carolina, United States, 27106
-
-
Oregon
-
Portland, Oregon, United States, 97239
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
-
-
Texas
-
Austin, Texas, United States, 78759
-
Dallas, Texas, United States, 75230
-
Houston, Texas, United States, 77056
-
San Antonio, Texas, United States, 78229
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
-
West Jordan, Utah, United States, 84088
-
-
Virginia
-
Lynchburg, Virginia, United States, 24501
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- In good general health
- Have 5 to 20 AKs on the face or balding scalp
- Negative urine pregnancy test (for women who are able to become pregnant)
- Willing to make frequent visits to the study center during treatment and follow-up periods.
Exclusion Criteria:
- Women who are pregnant, lactating or planning to become pregnant during the study.
- Have had a medical event within 90 days of the first visit (such as; stroke, heart attack).
- Have any skin condition in the treatment area that may be made worse by treatment with imiquimod (e.g., rosacea, psoriasis, atopic dermatitis, eczema).
- Have received specific treatments/medications in the treatment area(s) within the designated time period prior to study treatment initiation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo cream
|
cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles.
The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
|
Active Comparator: 3.75% imiquimod cream
|
cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles.
The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
|
Active Comparator: 2.5% imiquimod cream
|
cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles.
The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Complete Clearance of AK Lesions
Time Frame: End of Study the Week 14 visit
|
Subject status with respect to complete clearance of AK lesions at End of Study (EOS), ie, the Week 14 visit.
Complete clearance was defined as the absence of clinically visible or palpable AK lesions in the treatment area.
All lesions within the identified treatment area were included in the count, even if the lesion was a new lesion or 'subclinical' lesion that had not been identified at Baseline.
|
End of Study the Week 14 visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Partial Clearance of AK Lesions
Time Frame: End of Study the Week 14 visit
|
Subject status with respect to partial clearance of AK lesions at end of study (EOS), defined as at least a 75% reduction in the number of AK lesions in the treatment area compared with Baseline.
|
End of Study the Week 14 visit
|
Percent Change From Baseline in AK Lesion Count
Time Frame: From baseline to End of Study the Week 14 visit
|
Percent change from Baseline to end of study (EOS) in investigator counts of AK lesions.
|
From baseline to End of Study the Week 14 visit
|
Local Skin Reactions
Time Frame: At all visits - from Baseline to End of study (Week 14)
|
Six local skin reaction (LSR) signs were predefined and were assessed for presence and intensity at each study visit.
These included: Erythema, Edema, Weeping/Exudate, Flaking/Scaling/Dryness, Scabbing/Crusting and Erosion/Ulceration.
The LSRs were scored as 0=none, 1=mild, 2=moderate, 3=severe.
Mean scores were summated over time (14 weeks) to yield a mean LSR AUC (area under the curve)
|
At all visits - from Baseline to End of study (Week 14)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sharon F Levy, MD, Graceway Pharmaceuticals
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GW01-0702 / 0704
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratoses
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
-
PeplinCompleted
Clinical Trials on imiquimod cream
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States
-
Taro Pharmaceuticals USACompleted
-
Graceway Pharmaceuticals, LLCCompletedKeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedSuperficial Basal Cell CarcinomaAustralia, New Zealand
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States, Canada
-
Teva Pharmaceuticals USACompletedActinic KeratosisUnited States
-
Medicis Global Service CorporationUnknownActinic KeratosisUnited States